SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter-2 (SGLT2) inhibitors (SGLT2is) are known for the treatment of T2DM and show the effect on kidney SGLT2, which results in the reduction in blood glucose levels (shown in Figure 3).